logo_ProQR-150x150.png
ProQR Announces Second Quarter 2024 Operating and Financial Results
August 08, 2024 07:00 ET | ProQR Therapeutics N.V.
AX-0810 program targeting NTCP for cholestatic diseases and AX-1412 program targeting B4GALT1 for cardiovascular diseases advancing to the clinic in late 2024/early 2025 with translational data and...
logo_ProQR-150x150.png
ProQR Announces First Quarter 2023 Operating and Financial Results
May 16, 2023 07:00 ET | ProQR Therapeutics N.V.
Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1Development of Axiomer® RNA base editing technology platform...
logo_ProQR-150x150.png
ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023
April 18, 2023 08:00 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA...
logo_ProQR-150x150.png
ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event
March 29, 2023 08:00 ET | ProQR Therapeutics N.V.
Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1; initiation of clinical trials anticipated in late 2024/early...
logo_ProQR-150x150.png
ProQR Announces Third Quarter 2022 Operating and Financial Results
November 09, 2022 07:00 ET | ProQR Therapeutics N.V.
Development of Axiomer® RNA base editing technology platform continues across multiple therapeutic areas; initial pipeline targets to be disclosed in early 2023 with Analyst and Investor R&D event...
logo_ProQR-150x150.png
ProQR Announces Webcast of Presentation at the Upcoming Stifel 2022 Healthcare Conference
November 03, 2022 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- LEIDEN, Netherlands & CAMBRIDGE, Mass., November 3, 2022 -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”),...
logo_ProQR-150x150.png
ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs
August 11, 2022 07:00 ET | ProQR Therapeutics N.V.
In line with corporate strategy update in April, ProQR to focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple therapeutic areas; update on initial...
logo_ProQR-150x150.png
ProQR Announces Second Quarter 2022 Operating and Financial Results
August 04, 2022 07:00 ET | ProQR Therapeutics N.V.
ProQR is accelerating the development of its Axiomer® RNA base-editing technology platform across multiple therapeutic areas and will provide an update on first targets in H2 2022Company plans to...
logo_ProQR-150x150.png
ProQR to Participate in the Kempen Life Sciences Conference
April 19, 2022 16:30 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
logo_ProQR-150x150.png
ProQR to Present Axiomer RNA Editing Platform Technology at RNA Editing Summit
April 04, 2022 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...